Ptc Therapeutics (PTCT) Capital Leases (2020 - 2025)

Ptc Therapeutics' Capital Leases history runs 6 years deep, the most recent figure standing at $3.0 million for Q4 2025.

• In Q4 2025, Capital Leases fell 80.74% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $3.0 million (down 80.74% YoY), while the FY2025 annual figure was $3.0 million, down 80.74% from the prior year.
• Capital Leases was $3.0 million for Q4 2025 at Ptc Therapeutics, down from $13.8 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $20.1 million in Q1 2021 to a low of $3.0 million in Q4 2025.
• Historically, Capital Leases has averaged $16.5 million across 5 years, with a median of $17.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Capital Leases retreated 6.75% in 2022, then slumped 80.74% in 2025.
• A 5-year view of Capital Leases shows it stood at $20.1 million in 2021, then fell by 6.87% to $18.7 million in 2022, then dropped by 7.98% to $17.2 million in 2023, then retreated by 9.37% to $15.6 million in 2024, then plunged by 80.74% to $3.0 million in 2025.
• The last three Capital Leases figures came in at $3.0 million (Q4 2025), $13.8 million (Q3 2025), and $13.8 million (Q2 2025), per Business Quant data.